Press ReleasesPress ReleasesQuarterly ResultsIsoray to Present at the H.C. Wainwright BioConnect 2021 ConferenceJanuary 7, 2021Isoray’s Cesium-131 Spotlighted in Multiple Presentations at ASTRONovember 24, 2020Isoray Announces First Quarter Fiscal 2021 Financial ResultsNovember 10, 2020Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020November 2, 2020Isoray, Inc. Announces Pricing of $9.5 Million Public OfferingOctober 20, 2020Isoray, Inc. Announces Proposed Underwritten Public OfferingOctober 19, 2020Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial ResultsSeptember 17, 2020Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitSeptember 16, 2020Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020September 10, 2020Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck CancersJune 17, 2020Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate CancerJune 2, 2020Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131May 12, 20204 12345678 5
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial ResultsSeptember 17, 2020
Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitSeptember 16, 2020
Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020September 10, 2020
Isoray and University of Cincinnati Physicians Company Sign Research Agreement to Study Treatment of Head and Neck CancersJune 17, 2020
Second Ten Year Data Report Demonstrates Efficacy of Isoray’s Cesium-131 Internal Radiation Therapy in the Treatment of Prostate CancerJune 2, 2020
Centers for Medicare and Medicaid Services Approves Isoray’s Application for Billing Codes for the Intraoperative Use of Cesium-131May 12, 2020
